Indian Scientists Develop Cancer-Targeting Drug That May Replace Chemotherapy

What if a cancer drug could remain largely quiet while travelling through the body but switch on when it reaches the hostile chemical environment inside a tumour?

That is the idea behind RK-251, an experimental “smart” drug developed by scientists from the Institute of Advanced Study in Science and Technology (IASST) and IIT-Guwahati.

The research, published in the Journal of Medicinal Chemistry in July 2026, describes RK-251 as a reactive oxygen species (ROS)-responsive prodrug designed to selectively release the anticancer compound NBDHEX inside cancer cells.

The study was led by Dr Asis Bala of IASST and Dr Krishna P. Bhabak of IIT-Guwahati, along with their collaborators.

The concept addresses one of chemotherapy's enduring problems: its inability to completely distinguish cancerous cells from healthy ones. Because many conventional anticancer drugs affect rapidly dividing normal cells as well as tumour cells, treatment can cause significant adverse effects.

RK-251 attempts to make that distinction biologically. Cancer cells often carry elevated levels of reactive oxygen species. The researchers designed the compound to exploit this difference. When exposed to ROS, RK-251 undergoes activation and releases NBDHEX, which inhibits glutathione-S-transferase pi (GSTP1), a protein implicated in cancer-cell survival and drug resistance. The activation also produces a near-infrared fluorescence signal, potentially offering an additional way of tracking the drug's behaviour, as per the study.

The approach is particularly significant in the context of breast cancer, which remains India's most frequently diagnosed cancer. According to the International Agency for Research on Cancer's GLOBOCAN 2022 estimates, India recorded about 14.13 lakh new cancer cases and 9.17 lakh cancer deaths in 2022. Breast cancer accounted for about 1.92 lakh new cases, making it the country's leading cancer type overall and among women.

Globally, breast cancer is also a major part of the cancer burden. IARC estimates that more than 2.31 million new breast cancer cases were recorded worldwide in 2022, making it the second most commonly diagnosed cancer after lung cancer and the most commonly diagnosed cancer among women.

The Indian research specifically tested RK-251 against triple-negative breast cancer (TNBC) cells, an aggressive form of breast cancer that lacks three commonly targeted receptors and therefore presents particular therapeutic challenges.

In laboratory experiments, the compound demonstrated potent activity against TNBC cells compared with non-malignant cells.

But the findings remain firmly at the preclinical stage. The researchers also studied the compound in developing zebrafish embryos. The experiments showed the expected fluorescence response in the presence of ROS and no noticeable abnormalities or acute toxicity under the conditions tested. These findings support further investigation but do not establish that the drug is safe or effective in humans.

Now, researchers will need to establish its safety, pharmacological behaviour, optimal dose, effectiveness in relevant animal models and, eventually, its benefit-risk profile in patients.

According to oncologists, cancer treatment is increasingly moving towards precision — identifying the biological weaknesses of tumour cells and designing therapies around them rather than exposing the entire body to a drug's effects.

India's cancer burden makes such innovation particularly relevant, they said.

As per the IARC data, breast, cervical and lip/oral cancers together account for roughly a third of cancer diagnoses in India, while early detection remains crucial because these cancers can often be treated more successfully when identified at an early stage.

For RK-251, said the experts, the road ahead is therefore as important as the discovery itself. The molecule has demonstrated a compelling proof of concept: a drug that uses the biology of cancer cells to determine when to become active.

Though it is too early to say that RK-251 can replace chemotherapy, the research points towards a future in which cancer treatment could become more selective, more trackable and potentially less damaging to healthy tissue.